These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 21246)

  • 1. The roles of presynaptic function and hepatic drug metabolism in the hypothermic actions of two novel dopaminergic agonists.
    Silbergeld EK; Adler H; Kennedy S; Calne DB
    J Pharm Pharmacol; 1977 Oct; 29(10):632-5. PubMed ID: 21246
    [No Abstract]   [Full Text] [Related]  

  • 2. Differential effects of three dopamine agonists: apomorphine, bromocriptine and lergotrile.
    Silbergeld EK; Pfeiffer RF
    J Neurochem; 1977 Jun; 28(6):1323-6. PubMed ID: 577501
    [No Abstract]   [Full Text] [Related]  

  • 3. Hypothermic action of lisuride in rats and differences to bromocriptine in the antagonistic effect of neuroleptics.
    Horowski R
    Naunyn Schmiedebergs Arch Pharmacol; 1979 Mar; 306(2):147-51. PubMed ID: 36572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central dopamine agonistic activity and microsomal biotransformation of lisuride, lergotrile and bromocriptine.
    Keller HH; Da Prada M
    Life Sci; 1979 Mar; 24(13):1211-21. PubMed ID: 36540
    [No Abstract]   [Full Text] [Related]  

  • 5. Bromocriptine, dihydroergotoxine, methysergide, d-LSD, CF25--397, and 29--712: effects on the metabolism of the biogenic amines in the brain of the rat.
    Bürki HR; Asper H; Ruch W; Züger PE
    Psychopharmacology (Berl); 1978 May; 57(3):227-37. PubMed ID: 97702
    [No Abstract]   [Full Text] [Related]  

  • 6. Lergotrile mesylate: an in vivo dopamine agonist which blocks dopamine receptors in vitro.
    Kebabian JW; Calne DB; Kebabian PR
    Commun Psychopharmacol; 1977; 1(4):311-8. PubMed ID: 615694
    [No Abstract]   [Full Text] [Related]  

  • 7. Hypothermic action of bromocriptine.
    Calne DB; Claveria LE; Reid JL
    Br J Pharmacol; 1975 May; 54(1):123-4. PubMed ID: 1139073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of levodopa, lergotrile, and bromocriptine on brain iron, manganese, and copper.
    Weiner WJ; Nausieda PA; Klawans HL
    Neurology; 1978 Jul; 28(7):734-7. PubMed ID: 566875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of L-dopa and lergotrile mesylate on the interaction of fluphenazine decanoate and amphetamine-induced stereotypy and mortality.
    Lemberger L; Kellams JJ; Small JG; Rowe H
    Commun Psychopharmacol; 1977; 1(5):501-7. PubMed ID: 564259
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of bromocriptine in the rat.
    Schran HF; Tse FL; Bhuta SI
    Biopharm Drug Dispos; 1985; 6(3):301-11. PubMed ID: 4041556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bromocriptine and lisuride stimulate the accumulation of cyclic AMP in intact slices but not in homogenates of rat neostriatum.
    Saiani L; Trabucchi M; Tonon GC; Spano PF
    Neurosci Lett; 1979 Sep; 14(1):31-6. PubMed ID: 231228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperprolactinaemia and antihypertensive effect of bromocriptine in essential hypertension. Identification of abnormal central dopamine control.
    Stumpe KO; Kolloch R; Higuchi M; Krück F; Vetter H
    Lancet; 1977 Jul; 2(8031):211-4. PubMed ID: 69827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Central dopaminergic and noradrenergic components of bromocryptine-induced locomotor activity in mice [proceedings].
    Dolphin AC; Jenner P; Marsden CD; Sawaya MC
    Br J Pharmacol; 1977 Mar; 59(3):467P. PubMed ID: 576587
    [No Abstract]   [Full Text] [Related]  

  • 14. Autoreceptors mediate the inhibition of dopamine synthesis by bromocriptine and lisuride in rats.
    Tissari AH; Rossetti ZL; Meloni M; Frau MI; Gessa GL
    Eur J Pharmacol; 1983 Aug; 91(4):463-8. PubMed ID: 6413231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of serotoninergic neurons in the hyperthermic response to dopaminergic agonists.
    Carruba MO; Tofanetti O; Picotti GB; Mantegazza P
    Pharmacol Res Commun; 1978 Apr; 10(4):357-70. PubMed ID: 150605
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of haloperidol pre- and post-treatment on the ability of pergolide and bromocriptine to antagonize the gamma-butyrolactone-induced increase in brain dopamine in rats.
    Fuller RW; Perry KW
    Biochem Pharmacol; 1982 Jun; 31(12):2199-200. PubMed ID: 7115441
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of bromocriptine on central dopaminergic receptors.
    Trabucchi M; Spano PF; Tonon GC; Frattola L
    Life Sci; 1976 Jul; 19(2):225-31. PubMed ID: 183071
    [No Abstract]   [Full Text] [Related]  

  • 18. Inhibition of the plasma-aldosterone response to frusemide by bromocriptine.
    Edwards CR; Miall PA; Hanker JP; Thorner MO; Al-Dujaili EA; Besser GM
    Lancet; 1975 Nov; 2(7941):903-5. PubMed ID: 53377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolactin, bromocriptine and dopaminergic neurotransmission.
    Lamberts SW; Birkenhäger JC
    Neth J Med; 1976; 19(3):113-7. PubMed ID: 6921
    [No Abstract]   [Full Text] [Related]  

  • 20. Bromocriptine: a rather specific stimulant of dopamine receptors regulating dopamine metabolism.
    Di Chiara G; Vargiu L; Porceddu ML; Gessa GL
    Adv Biochem Psychopharmacol; 1977; 16():443-6. PubMed ID: 578073
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.